Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTSH for Radioiodine Treatment in Differentiated Thyroid Cancer
NCT06405217Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
Randomised, open-label trial of thyrotropin alfa in differentiated thyroid cancer (DTC) (2 arms), sponsored by Nanjing First Hospital. Primary endpoints: Rate of thyroid stimulating hormone elevation and Incidence of Treatment-Emergent Adverse Events at 3 months. Started Apr 2024; status: recruiting.
02
Drugs
thyrotropin alfa
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT06405217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405217.